Physician profile
Brad A Factor
NPI 1962438531
$2,244.77
in general payments reported to CMS, 2019-2025
25 companies · $384 in 2025
The $384 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53.03 · 2020: $16.83 · 2021: $227 · 2022: $156 · 2023: $442 · 2024: $966 · 2025: $384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,792.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,792.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $296.35 | 2021-2025 | Enhertu |
| Elekta, INC. | $269.94 | 2024 | Elekta Medical Linear Accelerator |
| Astrazeneca Pharmaceuticals LP | $247.63 | 2023-2025 | Imfinzi, Enhertu |
| Novartis Pharmaceuticals Corporation | $228.04 | 2020-2025 | |
| Siemens Medical Solutions USA, INC. | $177.17 | 2024 | |
| Lilly USA, LLC | $138.36 | 2022-2023 | Verzenio, Retevmo, Jaypirca |
| Incyte Corporation | $119.80 | 2022-2024 | Jakafi, Monjuvi, Pemazyre |
| Foundation Medicine, INC. | $117.88 | 2021 | |
| Merck Sharp & Dohme LLC | $83.75 | 2024-2025 | Keytruda, Lynparza |
| Seagen INC. | $70.88 | 2021-2023 | Tukysa, Padcev |
| Amgen INC. | $48.73 | 2021-2022 | |
| Adc Therapeutics America, INC. | $47.35 | 2024-2025 | |
| Stryker Corporation | $47.05 | 2023 | N/A |
| Eisai INC. | $46.55 | 2019-2024 | |
| Genzyme Corporation | $45.09 | 2023-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $40.66 | 2022-2025 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $39.99 | 2022-2024 | Iclusig |
| Genentech USA, INC. | $33.33 | 2024 | Venclexta, Polivy |
| Myriad Genetic Laboratories, INC. | $28.81 | 2023 | Prolaris |
| Puma Biotechnology, INC. | $25.40 | 2021 | |
| Glaxosmithkline, LLC. | $23.95 | 2024 | Jemperli, Zejula |
| Brainlab, INC. | $20.29 | 2024 | Surgical Planning and Navigation Radiation Treatment Planning and Positioning |
| Blue Earth Diagnostics | $17.23 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.15 | 2019 | |
| Boston Scientific Corporation | $13.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brad Factor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.